Floatz logo

FILGRASTIM

Recurrent Adult Soft Tissue Sarcoma

University of California, Irvineprotein_peptidePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Recurrent Adult Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
GI Innovation, Inc.
Phase 2BBB
Evomela
Albert Einstein College of Medicine
Phase 2BB
Irinotecan
GI Innovation, Inc.
Phase 1/2BB
Olaparib
OHSU Knight Cancer Institute
Phase 2BB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2B

View all 33 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →